

KEEPING KIDS IN TUNE



Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients.

Investment Highlights

- ❖ US Orphan Drug Designation (7.5 years market exclusivity)
 - Potential for European Market Exclusivity for Pediatric Use (10 years)
- ❖ Completed enrollment of two Phase 3 trials
- ❖ COG Phase 3 trial achieved primary endpoint for hearing
 - Achieved primary efficacy endpoint of greater than 50% improvement in hearing
- ❖ SIOPEL 6 Phase 3 trial reported no adverse outcomes of STS plus Cisplatin vs. Cisplatin alone
 - Efficacy results (primary endpoint of hearing loss) expected in 2017 when all children have reached 3.5 years of age
 - Protocol pre-specified second interim analysis on 68 patients planned in the first half of 2016 - Early stopping criteria met if p value of <0.016
- ❖ Significant unmet medical need with no approved treatment on market or in development
- ❖ Fennec has exclusive regulatory rights to data from both studies
- ❖ Well positioned to initiate discussions with US & European regulators once hearing data is available from SIOPEL 6

Recent News

- 12/9/15 Fennec announces new Chairman of the Board Khalid Islam
- 5/31/15 Fennec announces presentation of positive interim Sodium Thiosulfate Phase 3 safety data at the ASCO Annual Meeting
- 4/1/15 Fennec announces the exercise of warrants by the Company's largest shareholder
- 2/2/15 Fennec announces that the Independent Monitoring Committee (IDMC) recommends the continuation of the SIOPEL 6 Phase 3 Clinical Trial
- 1/5/15 Fennec announces completion of patient enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
- 12/3/14 Fennec announces private placement of units for gross proceeds of USD\$2.2 million
- 6/2/14 Fennec announces COG Study ACCL0431 Phase 3 Clinical Trial for Sodium Thiosulfate meets primary endpoint for prevention of cisplatin-induced hearing loss in children

About the Company:

TSX	FRX
OTCQB	FENCF
Recent market price ¹	USD\$1.75
Shares Outstanding ²	10.9
Market capitalization ¹	USD\$19.0
Cash ²	USD\$1.4 million
Cash runway	2Q 2016
Debt	\$0

¹ March 1, 2016

² September 30, 2015

Board of Directors

Dr. Khalid Islam

Chairman of Board, Chairman and CEO at Gentium S.p.A. - sold to Jazz Pharma for \$1 billion

Adrian Haigh

Director, Currently SVP and General Manager PTC Therapeutics. Previously COO at Gentium S.p.A. - sold to Jazz Pharma for \$1 billion.

Chris Rallis

Director, Previously President & COO of Triangle Pharmaceuticals - sold to Gilead for \$500 million.

Steve Skolsky

Director, Currently Global Head of Site Management at Quintiles. Previously President and CEO of Sequoia Pharmaceuticals and CEO of Trimeris

Rosty Raykov, CEO & Director

Director, Wesdome Gold Mines

CONTACT

Rosty Raykov

Chief Executive Officer

Fennec Pharmaceuticals

9196365144

rroykov@fennecpharma.com

www.fennecpharma.com



FENNEC PHARMA